Genentech signs $105M upfront deal with Orionis Biosciences to develop molecular glue cancer drugs, with potential milestones ...

PureTech's deupirfenidone outperforms Roche's Esbriet in lung fibrosis trial, showing greater lung function preservation with ...

Altos, led by industry stalwarts Hal Barron and Hans Bishop, brought Dorian Therapeutics into its fold this week, according ...

ReproNovo raises $65M for trials of leflutrozole and nolasiban in reproductive health. CEO Jean Marie Duvall plans Phase 2 ...

Juvenescence is out with a $76 million Series B-1, its first equity funding since before the Covid-19 pandemic.

Two weeks into his tenure leading the FDA’s biologics center, Vinay Prasad has made his mark with a new framework for ...

The FDA's Oncologic Drugs Advisory Committee voted 8 to 1 against whether Genentech's pivotal trial is applicable to the US ...

The gene editing company CRISPR Therapeutics surprisingly struck a deal with China-based biotech Sirius Therapeutics to ...

Tourmaline Bio's drug pacibekitug reduced inflammation markers in heart disease study; company plans FDA talks for Phase 3 ...

Under the program that was first announced by President Trump last week, the US would target prices based on benchmarks from ...

Calibrate names Rob Rebak as new CEO, replacing Rob MacNaughton, amid executive changes. CFO and Chief Clinical Officer also ...

Pfizer is dishing out $1.25 billion upfront and up to $4.8 billion in milestone payments to Shenyang-based 3SBio for the ...